How Chemical Changes to Proteins Trigger Type 1 Diabetes—and Why Scientists Are Looking for Them

The human body makes roughly 20,000 different proteins based on genetic instructions. But the story doesn't end there. Once these proteins are built, they undergo chemical changes called post-translational modifications (PTMs). These modifications alter the shape and properties of proteins, creating millions of functional variants from the original genetic blueprint.

For the most part, these chemical tweaks are necessary and protective. But in autoimmune diseases like Type 1 diabetes, PTMs can create a problem: they can turn normal, healthy proteins into targets that the immune system recognizes as threats.

In Type 1 diabetes, one particularly important modification involves insulin. When insulin proteins undergo certain chemical changes, they can form a hybrid insulin peptide (HIP). This modified version looks different enough to the immune system that T cells trained to recognize it mount an attack—even though the underlying protein is part of the body's normal biology.

The immune system normally learns during development which proteins belong to the body and which are threats. This training process, called central tolerance, takes place in the thymus. But here's the catch: modified proteins like HIP may never appear in the thymus during this training phase. When they later show up in insulin-producing tissues, T cells haven't been trained to ignore them, and they treat them as invaders.

This process is amplified by inflammation, which upregulates the machinery that processes antigens, and by certain genetic variations in immune-related genes. The result is a cascade that pushes the immune system toward attacking insulin-producing cells.

Identifying which modified proteins trigger autoimmunity is challenging. To tackle this, scientists now use four complementary approaches. Mass spectrometry-based proteomics can directly detect modified proteins in tissues. Computational tools can predict which modified proteins are likely to bind to immune receptors. Antigen-directed methods test immune responses against specific modified proteins. And high-throughput T cell receptor screening can hunt for immune cells that recognize these modifications.

Each approach has strengths and limitations. Some are precise but slow; others are fast but require validation. The most powerful strategy involves combining multiple methods to build a complete picture of which modified proteins are present in disease and which ones actually trigger immune responses.

The review highlights three well-understood examples: citrullination in rheumatoid arthritis and other autoimmune disorders, hybrid insulin peptides in Type 1 diabetes, and deamidation of gluten in celiac disease. These examples show that different modifications, different tissues, and different genetic factors all shape which modified peptides become disease drivers.

Understanding how modified insulin peptides trigger autoimmunity opens new possibilities for detection and intervention. If scientists can reliably identify which people have immune responses to these modified proteins, they may be able to predict who will develop Type 1 diabetes earlier—before symptoms appear.

This knowledge could eventually inform new approaches to halting or delaying disease progression. While this research does not yet lead to treatment recommendations, it represents a fundamental shift in how scientists think about what actually triggers Type 1 diabetes at the molecular level.

Source: Immunological reviews. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.